Six months into 2026, there have already been notable FDA approvals, demonstrating further success for small-molecule drug discovery.
Twelve new chemical entities received FDA approval between January and mid-July, covering oncology, cardiometabolic disease, infectious disease, dermatology, psychiatry, anaesthesia, and now a landmark moment for oral peptide therapeutics. The headline approvals are hard to overlook. Orforglipron \(Foundayo, Eli Lilly\) became the first oral non-peptide GLP-1 receptor agonist to reach the market. Vepdegestrant \(Veppanu, Arvinas/Pfizer\) became the first approved PROTAC and enlicitide \(LIPFENDRA, Merck\) became the first FDA-approved oral PCSK9 inhibitor. The rest of the approved cohort rounds out a strong period for the field. Baxdrostat \(Baxfendy, AstraZeneca\) is the first aldosterone synthase inhibitor approved for hypertension. Sonrotoclax \(Beqalzi, BeOne Medicines\) is a next-generation BCL-2 inhibitor designed around the venetoclax resistance mutation G101V. Relacorilant \(Lifyorli, Corcept Therapeutics\) brought a selective glucocorticoid receptor antagonist to platinum-resistant ovarian cancer. Linerixibat \(Lynavoy, GSK\) is the first new mechanism-based option for cholestatic pruritus in primary biliary cholangitis in six decades. Zidebactam paired with cefepime in Zaynich \(Wockhardt\) addresses some of the hardest Gram-negative pathogens in clinical practice through two independent mechanisms. Ensitrelvir \(Xocova, Shionogi\) added a post-exposure prophylaxis indication for COVID-19. Cipepofol \(Cypsedo, Haisco Pharmaceutical\) is a cyclopropyl-modified propofol analogue and the first China-originated innovative intravenous anaesthetic to reach the U.S. market. Difamilast \(Adquey, Otsuka\) is a topical PDE4B-preferential inhibitor for atopic dermatitis. Milsaperidone \(Bysanti, Vanda Pharmaceuticals\) is an active metabolite of iloperidone approved for schizophrenia and bipolar I mania. The cohort as a whole tells a coherent structural story. Fused bicyclic nitrogen heterocycles dominate as scaffolds across targets as different as GPCRs, cytochrome P450 enzymes, and kinases. Bioisosteric replacement of carboxylic acids appears repeatedly. Every chiral compound in the set is a single defined enantiomer. Fluorinated aromatic motifs are a recurring feature. Enlicitide now adds a further dimension: oral macrocyclic peptides against protein-protein interaction targets, a chemical space that has promised much and, with this approval, finally delivered. What does this cohort tell you about where medicinal chemistry is heading? Could our building blocks be key to your next breakthrough? Explore our range at https://lnkd.in/eVbfw6Ua